142 related articles for article (PubMed ID: 25312286)
1. [IL-6 as a target in autoimmune disease and inflammation].
Hashizume M; Ohsugi Y
Nihon Yakurigaku Zasshi; 2014 Oct; 144(4):172-7. PubMed ID: 25312286
[No Abstract] [Full Text] [Related]
2. Immunotherapeutic implication of IL-6 blockade.
Tanaka T; Kishimoto T
Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.
Jones SA; Scheller J; Rose-John S
J Clin Invest; 2011 Sep; 121(9):3375-83. PubMed ID: 21881215
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of the interleukin-6 receptor.
Tanaka T; Narazaki M; Kishimoto T
Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.
Tanaka T; Narazaki M; Kishimoto T
FEBS Lett; 2011 Dec; 585(23):3699-709. PubMed ID: 21419125
[TBL] [Abstract][Full Text] [Related]
6. Anticytokine therapy in autoimmune diseases.
Nishimoto N; Kishimoto T; Yoshizaki K
Intern Med; 1999 Feb; 38(2):178-82. PubMed ID: 10225680
[TBL] [Abstract][Full Text] [Related]
7. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
8. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
Tanaka T; Narazaki M; Ogata A; Kishimoto T
Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines.
Murakami M; Kamimura D; Hirano T
Immunity; 2019 Apr; 50(4):812-831. PubMed ID: 30995501
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 as a therapeutic target in candidate inflammatory diseases.
Nishimoto N
Clin Pharmacol Ther; 2010 Apr; 87(4):483-7. PubMed ID: 20182422
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
[TBL] [Abstract][Full Text] [Related]
12. Hitting a complex target: an update on interleukin-6 trans-signalling.
Waetzig GH; Rose-John S
Expert Opin Ther Targets; 2012 Feb; 16(2):225-36. PubMed ID: 22324903
[TBL] [Abstract][Full Text] [Related]
13. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.
Ho LJ; Luo SF; Lai JH
Biochem Pharmacol; 2015 Sep; 97(1):16-26. PubMed ID: 26080005
[TBL] [Abstract][Full Text] [Related]
14. [Interleukin-6 From molecular mechanisms of signal transduction to physiological properties and therapeutic targeting].
Drutskaya MS; Nosenko MA; Atretkhany KS; Efimov GA; Nedospasov SA
Mol Biol (Mosk); 2015; 49(6):937-43. PubMed ID: 26710772
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
16. Gene of the month: Interleukin 6 (IL-6).
Ataie-Kachoie P; Pourgholami MH; Richardson DR; Morris DL
J Clin Pathol; 2014 Nov; 67(11):932-7. PubMed ID: 25031389
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6: Biology, signaling and strategies of blockade.
Schaper F; Rose-John S
Cytokine Growth Factor Rev; 2015 Oct; 26(5):475-87. PubMed ID: 26189695
[TBL] [Abstract][Full Text] [Related]
18. Can we design a better anti-cytokine therapy?
Drutskaya MS; Efimov GA; Kruglov AA; Nedospasov SA
J Leukoc Biol; 2017 Sep; 102(3):783-790. PubMed ID: 28546502
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.
Lane T; Gillmore JD; Wechalekar AD; Hawkins PN; Lachmann HJ
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S46-53. PubMed ID: 26120866
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
Jordan SC; Choi J; Kim I; Wu G; Toyoda M; Shin B; Vo A
Transplantation; 2017 Jan; 101(1):32-44. PubMed ID: 27547870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
